WSL
ABUS icon

Western Standard LLC’s Arbutus Biopharma ABUS Stock Holding History

Western Standard LLC’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.35M Buy
521,587
+13,734
+3% +$60.1K 1.23% 20
2025
Q4 		$2.44M Hold
507,853
– – 1.13% 17
2025
Q3 		$2.31M Buy
+507,853
New +$1.87M 0.68% 21

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Western Standard LLC's ABUS Position: Q1 2026 in Review

Western Standard LLC increased its Arbutus Biopharma (ABUS) stake by 2.7% in Q1 2026, buying an estimated $60.1K and bringing the position to 521,587 shares worth $2.35M. The position accounts for 1.23% of the portfolio, ranked #20.

Western Standard LLC first reported a position in ABUS in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.44M in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Western Standard LLC held 521,587 shares of Arbutus Biopharma worth $2.35M as of Q1 2026.
  • Western Standard LLC bought 13,734 Arbutus Biopharma shares in Q1 2026, an estimated $60.1K.
  • Arbutus Biopharma made up 1.23% of Western Standard LLC's portfolio in Q1 2026, its #20 holding.
  • Western Standard LLC first reported a position in Arbutus Biopharma in Q3 2025 and has held it in 3 quarters since.
  • Western Standard LLC's Arbutus Biopharma position peaked at $2.44M in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Western Standard LLC's 13F filing for Q1 2026, filed 5 May 2026.